This study demonstrates, for the first time, the principle and feasibility of vaccination with PDL1-Vax DCs to induce the production of anti-PD-L1 antibodies and to activate PD-L1-specific CTL responses capable of inhibiting PD-L1+ tumor growth. The gene discussed is CD274; the disease is neoplasm.